Journal profile · Oncology
Molecular Cancer Therapeutics
ISSN 1535-7163 · eISSN 1538-8514 · American Association for Cancer Research Inc. · UNITED STATES · Monthly · Founded 2001
Molecular Cancer Therapeutics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.4; hybrid open access; median 218 days to acceptance (114 articles, last 24 months); community-reported acceptance: about 50%; 612 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Cancer Therapeutics is published by American Association for Cancer Research Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer, Hypoxia, and Metabolism, Cancer-related Molecular Pathways and Monoclonal and Polyclonal Antibodies Research, together about 20.2% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology7.2%
- Cancer-related Molecular PathwaysMedicine7.1%
- Monoclonal and Polyclonal Antibodies ResearchMedicine5.9%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.7%
- HER2/EGFR in Cancer ResearchMedicine5.3%
- Lung Cancer Treatments and MutationsMedicine5%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.8%
- PI3K/AKT/mTOR signaling in cancerBiochemistry, Genetics and Molecular Biology4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.4LetPub ·
- CiteScore 2026-06
- 9.5LetPub ·
- SJR 2026-06
- 2.39LetPub ·
- SNIP 2026-06
- 1.1LetPub ·
- h-index
- 157LetPub ·
- h-index
- 220OpenAlex ·
- i10-index
- 5,250OpenAlex ·
- 2-year mean citedness
- 2.23OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 36.23%LetPub ·
Volume
- Articles per year
- 154LetPub ·
Articles by year OpenAlex count · 12,731 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 140 | 75 | 50 |
| 2025 | 612 | 100 | 666 |
| 2024 | 365 | 118 | 1,779 |
| 2023 | 720 | 115 | 2,713 |
| 2022 | 170 | 154 | 3,789 |
| 2021 | 524 | 193 | 8,096 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
218 daysMedian, submission to acceptance · P25–P75 169 days – 280 days
- Acceptance to online
- median 6 days (53 articles)
- Submission to online
- median 238 days
- Sample
- 114 articles with submission and acceptance dates (386 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Association for Cancer Research Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2001
- ISSN
- 1535-7163
- Electronic ISSN
- 1538-8514
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Molecular Cancer Therapeutics
What CAS zone is Molecular Cancer Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Cancer Therapeutics is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Cancer Therapeutics?
The latest impact factor listed by LetPub is 6.4; CiteScore 9.5, h-index 220.
How long does peer review take at Molecular Cancer Therapeutics?
Based on the dates recorded on 114 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 218 days (interquartile range 169–280 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular Cancer Therapeutics?
According to LetPub and DOAJ records, Molecular Cancer Therapeutics is indexed in SCIE and Scopus.
Is Molecular Cancer Therapeutics open access, and what is the APC?
Molecular Cancer Therapeutics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .